← 產業報告目錄

Drug Discovery Technologies Market by Product (Instruments, Reagents, Software), Technology (HTS, NGS, PCR, AI-based, Lab-on-chip), Process (Target Identification, Validation, Lead Optimization), Therapeutic Area (Oncology, CVD) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2026-01-15頁數 489報告編號 BT9820

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The drug discovery technologies market is expected to reach USD 51.51 billion in 2030 from USD 30.58 billion in 2025, at a CAGR of 11.0% during the forecast period. The market is driven by the increasing adoption of advanced screening platforms and the shift toward 3D cell cultures, organoids, and organ-on-a-chip models. These technologies improve disease relevance, enhance predictive accuracy, and support more efficient and reliable drug discovery processes. Furthermore, the shift towards targeted and precision therapies further boosts demand. However, high technology costs, complex workflows, and the need for skilled professionals continue to limit market growth. The in-silico/AI-based drug discovery segment is expected to grow at the highest CAGR during the forecast period. The in silico/AI-based drug discovery technology segment is growing at the highest CAGR in the drug discovery technologies market due to its ability to shorten discovery timelines, reduce costs, and improve success rates. These technologies use computational modeling, machine learning, and data analytics to rapidly identify and optimize drug candidates. By analyzing large biological and chemical datasets, AI-based platforms enable accurate target identification, lead screening, and toxicity prediction at early stages. This reduces reliance on trial-and-error laboratory methods and minimizes late-stage failures. Their scalability, speed, and ability to support precision medicine make in silico and AI-based technologies essential tools for pharmaceutical and biotechnology companies, driving strong adoption across the market. The oncology segment holds the largest share of the market. The oncology segment accounts for the largest share of the Drug Discovery Technologies Market. This growth is driven by the increasing prevalence of cancer worldwide and the rising focus on developing targeted and personalized therapies. Advanced screening platforms, high-throughput assays, and cell-based models are widely used to identify potential drug candidates, validate targets, and optimize leads. Strong investments in cancer research, expanding clinical pipelines, and growing collaboration between pharmaceutical companies and research institutes further support the adoption of these technologies. Improved drug development efficiency and the demand for more effective cancer treatments continue to drive growth in this segment globally. The US is expected to grow at the highest CAGR during the forecast period. The US is experiencing the highest growth in the drug discovery technologies market due to several factors. A strong presence of leading pharmaceutical and biotech companies, advanced research infrastructure, and a large number of ongoing oncology programs are key drivers. Increasing adoption of high-throughput screening, 3D cell models, and organ-on-a-chip platforms in cancer research is fueling demand. Supportive regulations, substantial public and private funding for biomedical research, and a focus on precision medicine further contribute to market expansion. Widespread use of advanced discovery technologies and robust collaborations between industry and research institutes enhance innovation, ensuring high-quality outputs and reinforcing North America’s leading position globally. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side – 70% and Demand Side– 30% • By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25% • By Region: North America – 40%, Europe – 25%, Asia Pacific – 25%, Latin America – 5%, the Middle East & Africa – 5% Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Illumina, Inc. (US), Revvity (US), F. Hoffmann-La Roche Ltd (Switzerland), Bruker (US), QIAGEN (Germany), Bio-Rad Laboratories, Inc. (US), Tecan Trading AG (Switzerland), Takara Bio Inc. (Japan), Corning Incorporated (US), Hamilton Company (US), PacBio (US), Oxford Nanopore Technologies plc (UK), Promega Corporation (US), Waters Corporation (US), Merck KGAA (Germany), Sartorius AG (Germany), BD (US), Eppendorf SE (Germany), Shimadzu Corporation (Japan), Aurora Biomed Inc. (Canada), Standard BioTools (US), Jeol Ltd. (Japan), Gilson Incorporated (US), BIOMÉRIEUX (France), Greiner AG (Austria), BGI Group (China), Porvair (UK), Polaris Genomics (US), BICO (Sweden), Creative Bioarray (US), Sphere Bio (UK), GenScript (UK), Schrödinger, Inc. (US), LECO Corporation (US), TransGen Biotech Co., Ltd. (China), BMG LABTECH (Germany), NanoTemper Technologies (Germany), MGI Tech Co., Ltd. (China), Araceli Biosciences (US), Sphere Bio (US), BioSolvelT GmbH (Germany), and Evosep (Denmark) are some of the key companies offering drug discovery technologies products. Research Coverage This research report categorizes the drug discovery technologies market by product (reagents & consumables, instruments, bioinformatics tools & software), technology (high-throughput screening technologies, next-generation sequencing, polymerase chain reaction, in-silico/AI-based drug discovery technologies, X-ray crystallography, chromatography, mass spectrometry, other technologies), process (target identification, target validation, hit-to-lead identification, lead optimization, candidate validation), therapeutic area (oncology, infectious diseases, cardiovascular diseases, neurological diseases, endocrine & metabolic diseases, autoimmune disorders, other therapeutic areas), end user (pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations (CROs), other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, And Africa). The report’s scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the drug discovery technologies market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the drug discovery technologies market. This report also includes a competitive analysis of emerging startups in the drug discovery technologies industry ecosystem. Key Benefits of Buying the Report The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (increasing adoption of advanced screening platforms, shift toward biologics and advanced therapeutic modalities, transition from conventional two-dimensional cultures to three-dimension models, technological innovations in assay miniaturization and automation), restraints (high up-front investment in instruments, automation, and data infrastructure and shortage of skilled personnel), opportunities (growing demand for in-silico based discovery and increasing need for specialized ADME/Toxicology testing), and challenges (assay reproducibility and standardization issues) influencing the market growth • Product Development/Innovation: Detailed insights into newly launched products and technological assessment of the drug discovery technologies market • Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the drug discovery technologies market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Illumina, Inc. (US), Revvity (US), among others, offering products for the drug discovery technologies market. Other companies include Polaris Genomics (US), BICO (Sweden), Creative Bioarray (US), Sphere Bio (UK), GenScript (UK), Schrödinger, Inc. (US), LECO Corporation (US), among others, for the drug discovery technologies market.
目錄 Table of Contents
1 INTRODUCTION 42 1.1 STUDY OBJECTIVES 42 1.2 MARKET DEFINITION 42 1.3 STUDY SCOPE 42 1.3.1 MARKET SEGMENTATION AND REGIONS COVERED 43 1.3.2 INCLUSIONS AND EXCLUSIONS 44 1.3.3 YEARS CONSIDERED 44 1.4 CURRENCY CONSIDERED 45 1.5 STAKEHOLDERS 45 1.6 SUMMARY OF CHANGES 45 2 EXECUTIVE SUMMARY 47 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 47 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 48 2.3 DISRUPTIVE TRENDS IN DRUG DISCOVERY TECHNOLOGIES MARKET 49 2.4 HIGH-GROWTH SEGMENTS 50 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 51 3 PREMIUM INSIGHTS 53 3.1 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT 53 3.2 DRUG DISCOVERY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 54 3.3 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2025 VS. 2030 (%) 55 4 MARKET OVERVIEW 56 4.1 INTRODUCTION 56 4.2 MARKET DYNAMICS 56 4.2.1 DRIVERS 57 4.2.1.1 Increasing adoption of advanced screening platforms 57 4.2.1.2 Shift toward biologics and advanced therapeutic modalities 58 4.2.1.3 Transition from conventional two-dimensional cultures to three-dimensional models 58 4.2.1.4 Technological innovations in assay miniaturization and automation 59 4.2.2 RESTRAINTS 59 4.2.2.1 High up-front investment in instruments, automation, and data infrastructure 59 4.2.2.2 Shortage of skilled personnel 60 4.2.3 OPPORTUNITIES 60 4.2.3.1 Growing demand for in-silico-based discovery 60 4.2.3.2 Increasing need for specialized ADME/Toxicology testing 60 4.2.4 CHALLENGES 61 4.2.4.1 Assay reproducibility and standardization issues 61 4.3 UNMET NEEDS AND WHITE SPACES 61 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 62 4.5 STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS 62 5 INDUSTRY TRENDS 64 5.1 PORTER’S FIVE FORCES ANALYSIS 64 5.1.1 INTENSITY OF COMPETITIVE RIVALRY 65 5.1.2 BARGAINING POWER OF SUPPLIERS 65 5.1.3 BARGAINING POWER OF BUYERS 66 5.1.4 THREAT OF SUBSTITUTES 66 5.1.5 THREAT OF NEW ENTRANTS 66 5.2 MACROECONOMIC OUTLOOK 66 5.2.1 INTRODUCTION 66 5.2.2 GDP TRENDS AND FORECAST 66 5.2.3 R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY 67 5.2.4 R&D TRENDS IN GLOBAL PHARMA INDUSTRY 67 5.3 VALUE CHAIN ANALYSIS 68 5.4 ECOSYSTEM ANALYSIS 69 5.5 PRICING ANALYSIS 71 5.5.1 AVERAGE SELLING PRICE OF END USERS, BY KEY PLAYER, 2024 71 5.5.2 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024 71 5.5.2.1 Average selling price of instruments, by key player, 2024 72 5.5.2.2 Average selling price of consumables, by key player, 2024 73 5.5.3 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY, 2022−2024 73 5.5.4 AVERAGE SELLING PRICE TREND, BY REGION, 2022–2024 74 5.6 TRADE ANALYSIS 75 5.6.1 IMPORT SCENARIO FOR HS CODE 3822.00 76 5.6.2 EXPORT SCENARIO FOR HS CODE 3822.00 76 5.6.3 IMPORT SCENARIO FOR HS CODE 9027.00 77 5.6.4 EXPORT SCENARIO FOR HS CODE 9027.00 78 5.7 KEY CONFERENCES AND EVENTS, 2025–2026 79 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 80 5.9 INVESTMENT AND FUNDING SCENARIO 80 5.10 CASE STUDY ANALYSIS 81 5.10.1 AI-DESIGNED IPF DRUG CANDIDATE ADVANCES IN CLINICAL DEVELOPMENT 81 5.10.2 INDUSTRY CONSORTIUM POOLS DATA TO IMPROVE AI-DRIVEN SMALL MOLECULE DISCOVERY 82 5.10.3 NEW AI FRAMEWORK FROM IIT MADRAS AND OHIO STATE STREAMLINES MOLECULAR DESIGN 82   5.11 IMPACT OF 2025 US TARIFF ON DRUG DISCOVERY TECHNOLOGIES MARKET 82 5.11.1 INTRODUCTION 82 5.11.2 KEY TARIFF RATES 82 5.11.3 PRICE IMPACT ANALYSIS 86 5.11.4 KEY IMPACT ON COUNTRIES/REGIONS 86 5.11.4.1 US 86 5.11.4.2 Europe 87 5.11.4.3 Asia Pacific 87 5.11.5 END-USE INDUSTRY IMPACT 87 5.11.5.1 Pharmaceutical and Biotechnology Companies 87 5.11.5.2 Academic and Research Institutes 88 5.11.5.3 Contract Research Organizations (CROs) 88 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 89 6.1 KEY EMERGING TECHNOLOGIES 89 6.1.1 HIGH-THROUGHPUT SCREENING (HTS) & AUTOMATION 89 6.1.2 AUTOMATED LIQUID HANDLING 89 6.2 ADJACENT TECHNOLOGIES 90 6.2.1 AI/ML-ENABLED & IN SILICO DISCOVERY PLATFORMS 90 6.2.2 DISCOVERY INFORMATICS & LAB DIGITALIZATION 90 6.3 TECHNOLOGY/PRODUCT ROADMAP 91 6.4 PATENT ANALYSIS 91 6.4.1 METHODOLOGY 91 6.4.2 NUMBER OF PATENTS FILED 91 6.4.3 LIST OF KEY PATENTS 93 6.5 FUTURE APPLICATIONS 94 6.6 IMPACT OF AI/GEN AI ON DRUG DISCOVERY TECHNOLOGIES MARKET 94 6.6.1 TOP USE CASES AND MARKET POTENTIAL 95 6.6.2 BEST PRACTICES IN AI-ENABLED DRUG DISCOVERY WORKFLOWS 96 6.6.3 CASE STUDIES OF AI IMPLEMENTATION IN DRUG DISCOVERY TECHNOLOGIES MARKET 96 6.6.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 96 6.6.5 CLIENTS’ READINESS TO ADOPT GENERATIVE MOLECULAR DESIGN IN DRUG DISCOVERY TECHNOLOGIES MARKET 97 7 SUSTAINABILITY AND REGULATORY LANDSCAPE 98 7.1 REGIONAL REGULATIONS AND COMPLIANCE 98 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98 7.1.2 INDUSTRY STANDARDS 100 7.1.2.1 North America 101 7.1.2.1.1 US 101 7.1.2.1.2 Canada 101 7.1.2.2 Europe 101 7.1.2.2.1 UK 102 7.1.2.3 Asia Pacific 102 7.1.2.3.1 China 102 7.1.2.3.2 Japan 103 7.1.2.3.3 India 103 7.1.2.3.4 South Korea 103 7.1.2.3.5 Australia 104 7.1.2.3.6 Rest of Asia Pacific 104 7.2 SUSTAINABILITY INITIATIVES 104 7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 105 7.4 CERTIFICATIONS, LABELING, ECO-STANDARDS 105 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOUR 107 8.1 DECISION-MAKING PROCESS 107 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 107 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 107 8.2.2 KEY BUYING CRITERIA, BY END USER 108 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 109 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 109 9 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT 111 9.1 INTRODUCTION 112 9.2 REAGENTS & CONSUMABLES 112 9.2.1 INNOVATIONS IN ASSAY CHEMISTRY AND SUPPLY CHAIN RESILIENCE TO PROMOTE GROWTH 112 9.3 INSTRUMENTS 116 9.3.1 HIGH-PERFORMANCE ANALYTICAL ATTRIBUTES AND AUTOMATION TO DRIVE MARKET 116 9.4 BIOINFORMATICS TOOLS & SOFTWARE 119 9.4.1 AI RISING ADOPTION OF AI AND MACHINE LEARNING FOR PREDICTIVE MODELING TO FUEL MARKET 119 10 DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY 123 10.1 INTRODUCTION 124 10.2 HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES 124 10.2.1 AUTOMATED LIQUID HANDLING 128 10.2.1.1 Increasing focus on precision, integration, and productivity to drive market 128 10.2.2 MICROPLATE-BASED HTS 132 10.2.2.1 Rising investments in pharmaceutical and biotechnology R&D to fuel market 132 10.2.3 LAB-ON-A CHIP 135 10.2.3.1 Increasing demand for more predictive preclinical models to boost market 135 10.2.4 LABEL-FREE TECHNOLOGY 139 10.2.4.1 Real-time, label-free interaction to accelerate segment growth 139 10.3 NEXT-GENERATION SEQUENCING 142 10.3.1 EXPANDED INTEGRATION OF ADVANCED NGS TECHNOLOGIES TO DRIVE MARKET 142 10.4 POLYMERASE CHAIN REACTION 146 10.4.1 ENHANCED POLYMERASE CHAIN REACTION INNOVATION AND AUTOMATION TO DRIVE MARKET 146 10.5 IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES 149 10.5.1 COMPUTATIONAL INTELLIGENCE AND COLLABORATIVE AI INNOVATIONS TO PROPEL MARKET 149 10.6 X-RAY CRYSTALLOGRAPHY 152 10.6.1 ADVANCED INSTRUMENTATION AND INNOVATIVE X-RAY TECHNIQUES TO BOOST MARKET 152 10.7 CHROMATOGRAPHY 156 10.7.1 REGULATORY PRESSURES AND COMPLEX BIOLOGICS R&D TO AID GROWTH 156 10.8 MASS SPECTROMETRY 159 10.8.1 INVESTMENT IN ADVANCED INSTRUMENTATION AND DATA-DRIVEN WORKFLOWS TO DRIVE MARKET 159 10.9 OTHER TECHNOLOGIES 163 11 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS 167 11.1 INTRODUCTION 168 11.2 TARGET IDENTIFICATION 168 11.2.1 INCREASING CLINICAL DATA VOLUME TO BOOST MARKET 168 11.3 TARGET VALIDATION 172 11.3.1 INCREASING TECHNOLOGICAL ADVANCEMENTS TO PROMOTE GROWTH 172 11.4 HIT-TO-LEAD IDENTIFICATION 175 11.4.1 GROWING ADOPTION OF MULTI-DISCIPLINARY APPROACHES TO DRIVE MARKET 175 11.5 LEAD OPTIMIZATION 179 11.5.1 INCREASING FOCUS ON REDUCING LATE-STAGE ATTRITION AND INCREASING PROBABILITY OF THERAPEUTIC SUCCESS TO FUEL MARKET 179 11.6 CANDIDATE VALIDATION 182 11.6.1 INCREASING COMPLEXITY OF THERAPEUTIC MODALITIES TO SUSTAIN GROWTH 182 12 DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA 186 12.1 INTRODUCTION 187 12.2 ONCOLOGY 187 12.2.1 SHIFT TOWARD PRECISION ONCOLOGY TO PROMOTE GROWTH 187   12.3 INFECTIOUS DISEASES 191 12.3.1 RISING ANTIMICROBIAL RESISTANCE AND AI-DRIVEN INNOVATIONS TO DRIVE MARKET 191 12.4 CARDIOVASCULAR DISEASES 194 12.4.1 INCREASING PREVALENCE OF CARDIOVASCULAR RISK FACTORS TO BOOST MARKET 194 12.5 NEUROLOGICAL DISEASES 198 12.5.1 INTEGRATION OF ADVANCED MODELS AND STRATEGIC INVESTMENTS TO FUEL MARKET 198 12.6 ENDOCRINE & METABOLIC DISORDERS 201 12.6.1 RISING PREVALENCE OF TYPE 2 DIABETES, OBESITY, AND ASSOCIATED METABOLIC SYNDROMES TO DRIVE MARKET 201 12.7 AUTOIMMUNE DISORDERS 205 12.7.1 WIDESPREAD ADOPTION OF BIOLOGICS AND SMALL MOLECULES TO PROPEL MARKET 205 12.8 OTHER THERAPEUTIC AREAS 208 13 DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER 212 13.1 INTRODUCTION 213 13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 213 13.2.1 TECHNOLOGY INTEGRATION AND STRATEGIC PARTNERSHIPS TO CONTRBUTE TO GROWTH 213 13.3 ACADEMIC & RESEARCH INSTITUTES 217 13.3.1 RISING PUBLIC AND PRIVATE RESEARCH FUNDING AND STRONGER ACADEMIC–INDUSTRY COLLABORATION FRAMEWORKS TO AUGMENT GROWTH 217 13.4 CONTRACT RESEARCH ORGANIZATIONS (CROS) 220 13.4.1 INCREASING R&D OUTSOURCING TO EXPEDITE GROWTH 220 14 DRUG DISCOVERY TECHNOLOGIES MARKET, BY REGION 224 14.1 INTRODUCTION 225 14.2 NORTH AMERICA 225 14.2.1 US 230 14.2.1.1 Expanding network of cross-border partnerships and investments to expedite growth 230 14.2.2 CANADA 233 14.2.2.1 Increasing adoption of AI and open-science models to accelerate growth 233 14.3 EUROPE 237 14.3.1 GERMANY 241 14.3.1.1 Strong network of publicly funded research institutes, contract research organizations, and pharmaceutical developers to boost market 241 14.3.2 UK 244 14.3.2.1 Increasing focus on next-generation computational platforms to promote growth 244 14.3.3 FRANCE 248 14.3.3.1 Robust innovation ecosystem and AI-enabled research to propel market 248 14.3.4 ITALY 251 14.3.4.1 Rising research funding to contribute to growth 251 14.3.5 SPAIN 255 14.3.5.1 Well-established network of research centers and universities to boost market 255 14.3.6 REST OF EUROPE 258 14.4 ASIA PACIFIC 262 14.4.1 CHINA 266 14.4.1.1 Global partnerships to propel market 266 14.4.2 JAPAN 270 14.4.2.1 Rising integration of AI and international partnerships to favor growth 270 14.4.3 INDIA 273 14.4.3.1 Domestic infrastructure enhancements and government initiatives to support growth 273 14.4.4 AUSTRALIA 277 14.4.4.1 Rising adoption of artificial intelligence and advanced computational tools to foster growth 277 14.4.5 SOUTH KOREA 280 14.4.5.1 Favorable public policies to support growth 280 14.4.6 REST OF ASIA PACIFIC 284 14.5 LATIN AMERICA 287 14.5.1 BRAZIL 291 14.5.1.1 Public-private collaborations to bolster growth 291 14.5.2 MEXICO 295 14.5.2.1 Rising demand for AI-powered research to support growth 295 14.5.3 REST OF LATIN AMERICA 298 14.6 MIDDLE EAST 302 14.6.1 GCC COUNTRIES 305 14.6.1.1 Saudi Arabia 309 14.6.1.1.1 Increasing focus on regulatory reform, research funding, and international partnerships to boost market 309 14.6.1.2 UAE 312 14.6.1.2.1 Strong government vision and cross-sector partnerships to aid growth 312 14.6.1.3 Rest of GCC countries 316 14.6.2 REST OF MIDDLE EAST 319 14.7 AFRICA 323 14.7.1 STRATEGIC PARTNERSHIPS AND CAPACITY BUILDING INITIATIVES TO PROPEL MARKET 323   15 COMPETITIVE LANDSCAPE 327 15.1 OVERVIEW 327 15.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN 327 15.3 REVENUE ANALYSIS 329 15.4 MARKET SHARE ANALYSIS 329 15.5 BRAND/PRODUCT COMPARISON 332 15.5.1 THERMO FISHER SCIENTIFIC INC. 333 15.5.2 MERCK KGAA 333 15.5.3 AGILENT TECHNOLOGIES, INC. 333 15.5.4 REVVITY 333 15.5.5 ILLUMINA, INC. 333 15.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 333 15.6.1 STARS 334 15.6.2 EMERGING LEADERS 334 15.6.3 PERVASIVE PLAYERS 334 15.6.4 PARTICIPANTS 334 15.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 336 15.6.5.1 Company footprint 336 15.6.5.2 Region footprint 337 15.6.5.3 Product footprint 338 15.6.5.4 Technology footprint 339 15.6.5.5 Process footprint 340 15.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 341 15.7.1 PROGRESSIVE COMPANIES 341 15.7.2 RESPONSIVE COMPANIES 341 15.7.3 DYNAMIC COMPANIES 341 15.7.4 STARTING BLOCKS 341 15.7.5 COMPETITIVE BENCHMARKING 343 15.7.5.1 Detailed list of key startups/SMEs 343 15.7.5.2 Competitive benchmarking of key startups/SMEs 344 15.8 COMPANY VALUATION AND FINANCIAL METRICS 345 15.9 COMPETITIVE SCENARIO 346 15.9.1 PRODUCT LAUNCHES 346 15.9.2 DEALS 347 15.9.3 EXPANSIONS 348 15.9.4 OTHER DEVELOPMENTS 348 16 COMPANY PROFILES 349 16.1 KEY PLAYERS 349 16.1.1 THERMO FISHER SCIENTIFIC INC. 349 16.1.1.1 Business overview 349 16.1.1.2 Products offered 350 16.1.1.3 Recent developments 353 16.1.1.3.1 Product launches 353 16.1.1.3.2 Deals 354 16.1.1.3.3 Expansions 354 16.1.1.4 MnM view 354 16.1.1.4.1 Key strengths/Right to win 354 16.1.1.4.2 Strategic choices 355 16.1.1.4.3 Weaknesses/Competitive threats 355 16.1.2 MERCK KGAA 356 16.1.2.1 Business overview 356 16.1.2.2 Products offered 357 16.1.2.3 Recent developments 358 16.1.2.3.1 Deals 358 16.1.2.3.2 Expansions 359 16.1.2.4 MnM view 359 16.1.2.4.1 Key strengths/Right to win 359 16.1.2.4.2 Strategic choices 359 16.1.2.4.3 Weaknesses/Competitive threats 359 16.1.3 AGILENT TECHNOLOGIES, INC. 360 16.1.3.1 Business overview 360 16.1.3.2 Products offered 361 16.1.3.3 Recent developments 363 16.1.3.3.1 Product launches 363 16.1.3.3.2 Expansions 364 16.1.3.4 MnM view 364 16.1.3.4.1 Key strengths/Right to win 364 16.1.3.4.2 Strategic choices 364 16.1.3.4.3 Weaknesses/Competitive threats 364 16.1.4 REVVITY 365 16.1.4.1 Business overview 365 16.1.4.2 Products offered 366 16.1.4.3 Recent developments 368 16.1.4.3.1 Product launches 368 16.1.4.3.2 Deals 368 16.1.4.3.3 Expansions 368 16.1.4.4 MnM view 369 16.1.4.4.1 Key strengths/Right to win 369 16.1.4.4.2 Strategic choices 369 16.1.4.4.3 Weaknesses/Competitive threats 369   16.1.5 ILLUMINA, INC. 370 16.1.5.1 Business overview 370 16.1.5.2 Products offered 371 16.1.5.3 Recent developments 372 16.1.5.3.1 Product launches 372 16.1.5.3.2 Deals 373 16.1.5.3.3 Expansions 373 16.1.5.3.4 Other developments 374 16.1.5.4 MnM view 374 16.1.5.4.1 Key strengths/Right to win 374 16.1.5.4.2 Strategic choices 374 16.1.5.4.3 Weaknesses/Competitive threats 374 16.1.6 DANAHER CORPORATION 375 16.1.6.1 Business overview 375 16.1.6.2 Products offered 376 16.1.6.3 Recent developments 380 16.1.6.3.1 Product launches 380 16.1.6.3.2 Deals 380 16.1.6.3.3 Expansions 381 16.1.6.4 MnM view 381 16.1.6.4.1 Key strengths/Right to win 381 16.1.6.4.2 Strategic choices 381 16.1.6.4.3 Weaknesses/Competitive threats 381 16.1.7 F. HOFFMANN-LA ROCHE LTD 382 16.1.7.1 Business overview 382 16.1.7.2 Products offered 383 16.1.7.3 Recent developments 385 16.1.7.3.1 Product launches 385 16.1.7.3.2 Deals 385 16.1.7.3.3 Other developments 385 16.1.8 BRUKER 386 16.1.8.1 Business overview 386 16.1.8.2 Products offered 387 16.1.8.3 Recent developments 388 16.1.8.3.1 Product launches 388 16.1.8.3.2 Deals 389 16.1.8.3.3 Expansions 389 16.1.9 QIAGEN 390 16.1.9.1 Business overview 390 16.1.9.2 Products offered 391 16.1.9.3 Recent developments 392 16.1.9.3.1 Product launches 392 16.1.9.3.2 Deals 393 16.1.9.3.3 Expansions 393 16.1.10 BIO-RAD LABORATORIES, INC. 394 16.1.10.1 Business overview 394 16.1.10.2 Products offered 395 16.1.10.3 Recent developments 397 16.1.10.3.1 Product launches 397 16.1.10.3.2 Deals 397 16.1.11 TECAN TRADING AG 398 16.1.11.1 Business overview 398 16.1.11.2 Products offered 400 16.1.12 TAKARA BIO INC. 401 16.1.12.1 Business overview 401 16.1.12.2 Products offered 402 16.1.12.3 Recent developments 403 16.1.12.3.1 Product launches 403 16.1.13 CORNING INCORPORATED 404 16.1.13.1 Business overview 404 16.1.13.2 Products offered 406 16.1.14 HAMILTON COMPANY 407 16.1.14.1 Business overview 407 16.1.14.2 Products offered 407 16.1.14.3 Recent developments 408 16.1.14.3.1 Product launches 408 16.1.14.3.2 Deals 408 16.1.15 PACBIO 409 16.1.15.1 Business overview 409 16.1.15.2 Products offered 410 16.1.15.3 Recent developments 412 16.1.15.3.1 Product launches 412 16.1.15.3.2 Expansions 412 16.1.16 OXFORD NANOPORE TECHNOLOGIES PLC 413 16.1.16.1 Business overview 413 16.1.16.2 Products offered 415 16.1.16.3 Recent developments 416 16.1.16.3.1 Product launches 416 16.1.16.3.2 Deals 416 16.1.17 PROMEGA CORPORATION 417 16.1.17.1 Business overview 417 16.1.17.2 Products offered 418   16.1.18 WATERS CORPORATION 419 16.1.18.1 Business overview 419 16.1.18.2 Products offered 421 16.1.18.3 Recent developments 422 16.1.18.3.1 Product launches 422 16.1.18.3.2 Deals 422 16.1.19 SARTORIUS AG 423 16.1.19.1 Business overview 423 16.1.19.2 Products offered 425 16.1.19.3 Recent developments 426 16.1.19.3.1 Deals 426 16.1.20 BD 427 16.1.20.1 Business overview 427 16.1.20.2 Products offered 428 16.1.20.3 Recent developments 429 16.1.20.3.1 Product launches 429 16.1.20.3.2 Deals 430 16.1.21 EPPENDORF SE 431 16.1.21.1 Business overview 431 16.1.21.2 Products offered 433 16.1.21.3 Recent developments 434 16.1.21.3.1 Deals 434 16.1.22 SHIMADZU CORPORATION 435 16.1.22.1 Business overview 435 16.1.22.2 Business overview 435 16.1.22.3 Products offered 436 16.1.23 AURORA BIOMED INC. 438 16.1.23.1 Business overview 438 16.1.23.2 Products offered 438 16.1.24 STANDARD BIOTOOLS 439 16.1.24.1 Business overview 439 16.1.24.2 Products offered 440 16.1.25 JEOL LTD. 441 16.1.25.1 Business overview 441 16.1.25.2 Products offered 443 16.1.26 GILSON INCORPORATED 444 16.1.26.1 Business overview 444 16.1.26.2 Products offered 444 16.1.27 BIOMÉRIEUX 445 16.1.27.1 Business overview 445 16.1.27.2 Products offered 446   16.1.28 GREINER AG 447 16.1.28.1 Business overview 447 16.1.28.2 Products offered 448 16.1.29 BGI GROUP 449 16.1.29.1 Business overview 449 16.1.29.2 Products offered 449 16.1.30 PORVAIR 451 16.1.30.1 Business overview 451 16.1.30.2 Products offered 452 16.2 OTHER PLAYERS 453 16.2.1 POLARIS GENOMICS 453 16.2.2 BICO 454 16.2.3 CREATIVE BIOARRAY 455 16.2.4 SPHERE BIO 455 16.2.5 GENSCRIPT 456 16.2.6 SCHRÖDINGER, INC. 457 16.2.7 LECO CORPORATION 458 16.2.8 TRANSGEN BIOTECH CO., LTD 459 16.2.9 BMG LABTECH 460 16.2.10 NANOTEMPER TECHNOLOGIES 461 16.2.11 MGI TECH CO., LTD. 462 16.2.12 ARACELI BIOSCIENCES 463 16.2.13 ANALYTIK JENA GMBH+CO. KG 464 16.2.14 BIOSOLVEIT GMBH 465 16.2.15 EVOSEP 466 17 RESEARCH METHODOLOGY 467 17.1 RESEARCH DATA 467 17.1.1 SECONDARY DATA 468 17.1.1.1 Key data from secondary sources 468 17.1.2 PRIMARY DATA 469 17.1.2.1 Key data from primary sources 469 17.1.2.2 Key primary participants 469 17.1.2.3 Breakdown of primary interviews 470 17.1.2.4 Key industry insights 471 17.2 MARKET SIZE ESTIMATION 472 17.2.1 BOTTOM-UP APPROACH 472 17.2.2 TOP-DOWN APPROACH 474 17.2.3 BASE NUMBER CALCULATION 475 17.3 GROWTH FORECAST MODEL 476 17.4 DATA TRIANGULATION 477 17.5 FACTOR ANALYSIS 478 17.6 RESEARCH ASSUMPTIONS 478 17.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT 479 18 APPENDIX 481 18.1 DISCUSSION GUIDE 481 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 485 18.3 CUSTOMIZATION OPTIONS 487 18.4 RELATED REPORTS 487 18.5 AUTHOR DETAILS 488
圖表清單 List of Tables & Figures
TABLE 1 DRUG DISCOVERY TECHNOLOGIES MARKET: INCLUSIONS AND EXCLUSIONS 44 TABLE 2 DRUG DISCOVERY TECHNOLOGIES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 57 TABLE 3 DRUG DISCOVERY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES 64 TABLE 4 DRUG DISCOVERY TECHNOLOGIES MARKET: ROLE OF COMPANIES IN ECOSYSTEM 70 TABLE 5 AVERAGE SELLING PRICE OF END USERS, BY KEY PLAYERS, 2024 71 TABLE 6 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024 (USD MILLION) 71 TABLE 7 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY, 2022−2024 73 TABLE 8 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION, 2022–2024 (USD MILLION) 74 TABLE 9 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY REGION, 2022–2024 (USD MILLION) 74 TABLE 10 IMPORT DATA FOR HS CODE 3822.00, BY COUNTRY, 2020–2024 (USD THOUSAND) 76 TABLE 11 EXPORT DATA FOR HS CODE 3822.00, BY COUNTRY, 2020–2024 (USD THOUSAND) 76 TABLE 12 IMPORT DATA FOR HS CODE 9027.00, BY COUNTRY, 2020–2024 (USD THOUSAND) 77 TABLE 13 EXPORT DATA FOR HS CODE 9027.00, BY COUNTRY, 2020–2024 (USD THOUSAND) 78 TABLE 14 DRUG DISCOVERY TECHNOLOGIES MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 79 TABLE 15 US ADJUSTED RECIPROCAL TARIFF RATES 82 TABLE 16 KEY PRODUCT-RELATED TARIFF: HS CODES FOR PRODUCTS RELEVANT TO DRUG DISCOVERY TECHNOLOGIES 85 TABLE 17 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES 86 TABLE 18 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014–2024 91 TABLE 19 LIST OF KEY PATENTS IN DRUG DISCOVERY TECHNOLOGIES MARKET, 2023–2025 93 TABLE 20 CASE STUDIES OF AI IMPLEMENTATION IN DRUG DISCOVERY TECHNOLOGIES MARKET 96 TABLE 21 CLIENT’S READINESS TO ADOPT GENERATIVE MOLECULAR DESIGN IN DRUG DISCOVERY TECHNOLOGIES MARKET 97 TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98 TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98 TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99 TABLE 25 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 100 TABLE 26 DRUG DISCOVERY TECHNOLOGIES MARKET: VENDOR CERTIFICATIONS 106 TABLE 27 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 108 TABLE 28 KEY BUYING CRITERIA, BY END USER 108 TABLE 29 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 112 TABLE 30 DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2023–2030 (USD MILLION) 113 TABLE 31 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 32 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 33 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 34 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 35 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2023–2030 (USD MILLION) 115 TABLE 36 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 37 DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION) 116 TABLE 38 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 39 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 40 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 41 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 42 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION) 119 TABLE 43 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 44 DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 120 TABLE 45 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 46 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 47 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 48 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 49 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 122 TABLE 50 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 51 DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 124 TABLE 52 DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 125 TABLE 53 DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION) 125 TABLE 54 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 55 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 56 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 57 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 58 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION) 128 TABLE 59 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 60 DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY REGION, 2023–2030 (USD MILLION) 129 TABLE 61 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 62 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 63 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 64 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 65 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY REGION, 2023–2030 (USD MILLION) 131 TABLE 66 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 67 DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY REGION, 2023–2030 (USD MILLION) 132 TABLE 68 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 69 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 70 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE- BASED HTS, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 71 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 72 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY REGION, 2023–2030 (USD MILLION) 135 TABLE 73 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 74 DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY REGION, 2023–2030 (USD MILLION) 136 TABLE 75 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 76 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 77 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 78 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 79 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY REGION, 2023–2030 (USD MILLION) 138 TABLE 80 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 81 DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY REGION, 2023–2030 (USD MILLION) 139 TABLE 82 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 83 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 84 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 85 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 86 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY REGION, 2023–2030 (USD MILLION) 142 TABLE 87 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 88 DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION) 143 TABLE 89 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 90 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 91 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 92 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 93 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION) 145 TABLE 94 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 95 DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION) 146 TABLE 96 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 97 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 98 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 99 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 100 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION) 149 TABLE 101 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 102 DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION) 150 TABLE 103 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 104 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 105 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 106 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 107 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 108 DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY REGION, 2023–2030 (USD MILLION) 153 TABLE 109 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 110 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 111 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 112 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 113 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY REGION, 2023–2030 (USD MILLION) 155 TABLE 114 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 115 DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY REGION, 2023–2030 (USD MILLION) 156 TABLE 116 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 117 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 118 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 119 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 120 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY REGION, 2023–2030 (USD MILLION) 159 TABLE 121 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 122 DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY REGION, 2023–2030 (USD MILLION) 160 TABLE 123 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 124 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 125 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 126 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 127 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY REGION, 2023–2030 (USD MILLION) 162 TABLE 128 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 129 DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION) 163 TABLE 130 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 131 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 132 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 133 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 134 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION) 166 TABLE 135 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 136 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 168 TABLE 137 DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION) 169 TABLE 138 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 139 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 140 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 141 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 142 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION) 171 TABLE 143 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 144 DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY REGION, 2023–2030 (USD MILLION) 172 TABLE 145 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 146 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 147 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 148 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 149 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY REGION, 2023–2030 (USD MILLION) 175 TABLE 150 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION,BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 151 DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION) 176 TABLE 152 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 153 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 154 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 155 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 156 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION) 178 TABLE 157 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 158 DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2023–2030 (USD MILLION) 179 TABLE 159 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 160 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 161 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 162 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 163 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2023–2030 (USD MILLION) 182 TABLE 164 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 165 DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2023–2030 (USD MILLION) 183 TABLE 166 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 167 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 184 TABLE 168 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 184 TABLE 169 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 170 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2023–2030 (USD MILLION) 185 TABLE 171 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 172 DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 187 TABLE 173 DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION) 188 TABLE 174 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 175 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 189 TABLE 176 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 189 TABLE 177 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 178 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION) 190 TABLE 179 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 190 TABLE 180 DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 191 TABLE 181 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 182 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 183 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 184 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 185 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 194 TABLE 186 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 187 DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION) 195 TABLE 188 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 195 TABLE 189 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 190 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 191 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 192 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION) 197 TABLE 193 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 194 DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION) 198 TABLE 195 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 196 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 199 TABLE 197 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 198 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 200 TABLE 199 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION) 201 TABLE 200 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 201 TABLE 201 DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2030 (USD MILLION) 202 TABLE 202 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 202 TABLE 203 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 203 TABLE 204 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 203 TABLE 205 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 204 TABLE 206 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2030 (USD MILLION) 204 TABLE 207 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 204 TABLE 208 DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2023–2030 (USD MILLION) 205 TABLE 209 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 206 TABLE 210 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 206 TABLE 211 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 207 TABLE 212 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 207 TABLE 213 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2023–2030 (USD MILLION) 208 TABLE 214 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 208 TABLE 215 DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 209 TABLE 216 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 209 TABLE 217 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 210 TABLE 218 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 210 TABLE 219 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 211 TABLE 220 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 211 TABLE 221 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 211 TABLE 222 DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 213 TABLE 223 DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 214 TABLE 224 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 214 TABLE 225 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 215 TABLE 226 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 215 TABLE 227 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 216 TABLE 228 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 216 TABLE 229 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 216 TABLE 230 DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 217 TABLE 231 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 218 TABLE 232 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 218 TABLE 233 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 219 TABLE 234 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 219 TABLE 235 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 220 TABLE 236 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 220 TABLE 237 DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2023–2030 (USD MILLION) 221 TABLE 238 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023–2030 (USD MILLION) 221 TABLE 239 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023–2030 (USD MILLION) 222 TABLE 240 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023–2030 (USD MILLION) 222 TABLE 241 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023–2030 (USD MILLION) 223 TABLE 242 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2023–2030 (USD MILLION) 223 TABLE 243 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023–2030 (USD MILLION) 223 TABLE 244 DRUG DISCOVERY TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 225 TABLE 245 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 226 TABLE 246 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 227 TABLE 247 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 227 TABLE 248 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 249 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 228 TABLE 250 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 229 TABLE 251 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 229 TABLE 252 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 230 TABLE 253 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 231 TABLE 254 US: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 231 TABLE 255 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 232 TABLE 256 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 232 TABLE 257 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 233 TABLE 258 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 234 TABLE 259 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 234 TABLE 260 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 235 TABLE 261 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 235 TABLE 262 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 236 TABLE 263 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 236 TABLE 264 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 237 TABLE 265 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 238 TABLE 266 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 238 TABLE 267 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 239 TABLE 268 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 239 TABLE 269 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 240 TABLE 270 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 240 TABLE 271 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 241 TABLE 272 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 242 TABLE 273 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 242 TABLE 274 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 243 TABLE 275 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 243 TABLE 276 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 244 TABLE 277 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 245 TABLE 278 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 245 TABLE 279 UK: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 246 TABLE 280 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 246 TABLE 281 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 247 TABLE 282 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 247 TABLE 283 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 248 TABLE 284 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 249 TABLE 285 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 249 TABLE 286 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 250 TABLE 287 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 250 TABLE 288 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 251 TABLE 289 ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 252 TABLE 290 ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 252 TABLE 291 ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 253 TABLE 292 ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 253 TABLE 293 ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 254 TABLE 294 ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 254 TABLE 295 SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 255 TABLE 296 SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 256 TABLE 297 SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 256 TABLE 298 SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 257 TABLE 299 SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 257 TABLE 300 SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 258 TABLE 301 REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 259 TABLE 302 REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 259 TABLE 303 REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 260 TABLE 304 REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 260 TABLE 305 REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 261 TABLE 306 REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 261 TABLE 307 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 263 TABLE 308 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 263 TABLE 309 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 264 TABLE 310 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 264 TABLE 311 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 265 TABLE 312 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 265 TABLE 313 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 266 TABLE 314 CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 267 TABLE 315 CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 267 TABLE 316 CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 268 TABLE 317 CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 268 TABLE 318 CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 269 TABLE 319 CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 269 TABLE 320 JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 270 TABLE 321 JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 271 TABLE 322 JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 271 TABLE 323 JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 272 TABLE 324 JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 272 TABLE 325 JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 273 TABLE 326 INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 274 TABLE 327 INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 274 TABLE 328 INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 275 TABLE 329 INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 275 TABLE 330 INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 276 TABLE 331 INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 276 TABLE 332 AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 277 TABLE 333 AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 278 TABLE 334 AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 278 TABLE 335 AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 279 TABLE 336 AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 279 TABLE 337 AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 280 TABLE 338 SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 281 TABLE 339 SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 281 TABLE 340 SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 282 TABLE 341 SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 282 TABLE 342 SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 283 TABLE 343 SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 283 TABLE 344 REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 284 TABLE 345 REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 285 TABLE 346 REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 285 TABLE 347 REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 286 TABLE 348 REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 286 TABLE 349 REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 287 TABLE 350 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 288 TABLE 351 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 288 TABLE 352 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 289 TABLE 353 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 289 TABLE 354 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 290 TABLE 355 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 290 TABLE 356 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 291 TABLE 357 BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 292 TABLE 358 BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 292 TABLE 359 BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 293 TABLE 360 BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 293 TABLE 361 BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 294 TABLE 362 BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 294 TABLE 363 MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 295 TABLE 364 MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 296 TABLE 365 MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 296 TABLE 366 MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 297 TABLE 367 MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 297 TABLE 368 MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 298 TABLE 369 REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 299 TABLE 370 REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 299 TABLE 371 REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 300 TABLE 372 REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 300 TABLE 373 REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 301 TABLE 374 REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 301 TABLE 375 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 302 TABLE 376 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 302 TABLE 377 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 303 TABLE 378 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 303 TABLE 379 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 304 TABLE 380 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 304 TABLE 381 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 305 TABLE 382 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 305 TABLE 383 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 306 TABLE 384 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 306 TABLE 385 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 307 TABLE 386 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 307 TABLE 387 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 308 TABLE 388 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 308 TABLE 389 SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 309 TABLE 390 SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 310 TABLE 391 SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 310 TABLE 392 SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 311 TABLE 393 SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 311 TABLE 394 SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 312 TABLE 395 UAE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 313 TABLE 396 UAE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 313 TABLE 397 UAE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 314 TABLE 398 UAE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 314 TABLE 399 UAE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 315 TABLE 400 UAE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 315 TABLE 401 REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 316 TABLE 402 REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 317 TABLE 403 REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 317 TABLE 404 REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 318 TABLE 405 REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 318 TABLE 406 REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 319 TABLE 407 REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 320 TABLE 408 REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 320 TABLE 409 REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 321 TABLE 410 REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 321 TABLE 411 REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 322 TABLE 412 REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 322 TABLE 413 AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 323 TABLE 414 AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 324 TABLE 415 AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 324 TABLE 416 AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 325 TABLE 417 AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 325 TABLE 418 AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 326 TABLE 419 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY TECHNOLOGIES MARKET, JANUARY 2022–NOVEMBER 2025 327 TABLE 420 DRUG DISCOVERY TECHNOLOGIES MARKET: DEGREE OF COMPETITION 330 TABLE 421 DRUG DISCOVERY TECHNOLOGIES MARKET: REGION FOOTPRINT 337 TABLE 422 DRUG DISCOVERY TECHNOLOGIES MARKET: PRODUCT FOOTPRINT 338 TABLE 423 DRUG DISCOVERY TECHNOLOGIES MARKET: TECHNOLOGY FOOTPRINT 339 TABLE 424 DRUG DISCOVERY TECHNOLOGIES MARKET: PROCESS FOOTPRINT 340 TABLE 425 DRUG DISCOVERY TECHNOLOGIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 343 TABLE 426 DRUG DISCOVERY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 344 TABLE 427 DRUG DISCOVERY TECHNOLOGIES MARKET: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 346 TABLE 428 DRUG DISCOVERY TECHNOLOGIES MARKET: DEALS, JANUARY 2022–NOVEMBER 2025 347 TABLE 429 DRUG DISCOVERY TECHNOLOGIES MARKET: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 348 TABLE 430 DRUG DISCOVERY TECHNOLOGIES MARKET: OTHER DEVELOPMENTS, JANUARY 2022–NOVEMBER 2025 348 TABLE 431 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 349 TABLE 432 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 350 TABLE 433 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 353 TABLE 434 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–NOVEMBER 2025 354 TABLE 435 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 354 TABLE 436 MERCK KGAA: COMPANY OVERVIEW 356 TABLE 437 MERCK KGAA: PRODUCTS OFFERED 357 TABLE 438 MERCK KGAA: DEALS, JANUARY 2022–NOVEMBER 2025 358 TABLE 439 MERCK KGAA: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 359 TABLE 440 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 360 TABLE 441 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 361 TABLE 442 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 363 TABLE 443 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 364 TABLE 444 REVVITY: COMPANY OVERVIEW 365 TABLE 445 REVVITY: PRODUCTS OFFERED 366 TABLE 446 REVVITY: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 368 TABLE 447 REVVITY: DEALS, JANUARY 2022–NOVEMBER 2025 368 TABLE 448 REVVITY: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 368 TABLE 449 ILLUMINA, INC.: COMPANY OVERVIEW 370 TABLE 450 ILLUMINA, INC.: PRODUCTS OFFERED 371 TABLE 451 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 372 TABLE 452 ILLUMINA, INC.: DEALS, JANUARY 2022–NOVEMBER 2025 373 TABLE 453 ILLUMINA, INC.: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 373 TABLE 454 ILLUMINA, INC.: OTHER DEVELOPMENTS, JANUARY 2022–NOVEMBER 2025 374 TABLE 455 DANAHER CORPORATION: COMPANY OVERVIEW 375 TABLE 456 DANAHER CORPORATION: PRODUCTS OFFERED 376 TABLE 457 DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 380 TABLE 458 DANAHER CORPORATION: DEALS, JANUARY 2022–NOVEMBER 2025 380 TABLE 459 DANAHER CORPORATION: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 381 TABLE 460 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 382 TABLE 461 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 383 TABLE 462 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 385 TABLE 463 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022–NOVEMBER 2025 385 TABLE 464 F. HOFFMANN-LA ROCHE LTD.: OTHER DEVELOPMENTS, JANUARY 2022–NOVEMBER 2025 385 TABLE 465 BRUKER: COMPANY OVERVIEW 386 TABLE 466 BRUKER: PRODUCTS OFFERED 387 TABLE 467 BRUKER: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 388 TABLE 468 BRUKER: DEALS, JANUARY 2022–NOVEMBER 2025 389 TABLE 469 BRUKER: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 389 TABLE 470 QIAGEN: COMPANY OVERVIEW 390 TABLE 471 QIAGEN: PRODUCTS OFFERED 391 TABLE 472 QIAGEN: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 392 TABLE 473 QIAGEN: DEALS, JANUARY 2022–NOVEMBER 2025 393 TABLE 474 QIAGEN: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 393 TABLE 475 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 394 TABLE 476 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 395 TABLE 477 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 397 TABLE 478 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022–NOVEMBER 2025 397 TABLE 479 TECAN TRADING AG: COMPANY OVERVIEW 398 TABLE 480 TECAN TRADING AG: PRODUCTS OFFERED 400 TABLE 481 TAKARA BIO INC.: COMPANY OVERVIEW 401 TABLE 482 TAKARA BIO INC.: PRODUCTS OFFERED 402 TABLE 483 TAKARA BIO INC.: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 403 TABLE 484 CORNING INCORPORATED: COMPANY OVERVIEW 404 TABLE 485 CORNING INCORPORATED: PRODUCTS OFFERED 406 TABLE 486 HAMILTON COMPANY: COMPANY OVERVIEW 407 TABLE 487 HAMILTON COMPANY: PRODUCTS OFFERED 407 TABLE 488 HAMILTON COMPANY: PRODUCT LAUNCHES 408 TABLE 489 HAMILTON COMPANY: DEALS 408 TABLE 490 PACBIO: COMPANY OVERVIEW 409 TABLE 491 PACBIO: PRODUCTS OFFERED 410 TABLE 492 PACBIO: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 412 TABLE 493 PACBIO: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 412 TABLE 494 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW 413 TABLE 495 OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCTS OFFERED 415 TABLE 496 OXFORD NANOPORE TECHNOLOGIES PLC.: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 416 TABLE 497 OXFORD NANOPORE TECHNOLOGIES PLC.: DEALS, JANUARY 2022–NOVEMBER 2025 416 TABLE 498 PROMEGA CORPORATION: COMPANY OVERVIEW 417 TABLE 499 PROMEGA CORPORATION: PRODUCTS OFFERED 418 TABLE 500 WATERS CORPORATION: COMPANY OVERVIEW 419 TABLE 501 WATERS CORPORATION: PRODUCTS OFFERED 421 TABLE 502 WATERS CORPORATION: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 422 TABLE 503 WATERS CORPORATION: DEALS, JANUARY 2022–NOVEMBER 2025 422 TABLE 504 SARTORIUS AG: COMPANY OVERVIEW 423 TABLE 505 SARTORIUS AG: PRODUCTS OFFERED 425 TABLE 506 SARTORIUS AG: DEALS, JANUARY 2022–NOVEMBER 2025 426 TABLE 507 BD: COMPANY OVERVIEW 427 TABLE 508 BD: PRODUCTS OFFERED 428 TABLE 509 BD: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 429 TABLE 510 BD: DEALS, JANUARY 2022–NOVEMBER 2025 430 TABLE 511 EPPENDORF SE: COMPANY OVERVIEW 431 TABLE 512 EPPENDORF SE: PRODUCTS OFFERED 433 TABLE 513 EPPENDORF SE: DEALS, JANUARY 2022–NOVEMBER 2025 434 TABLE 514 SHIMADZU CORPORATION: COMPANY OVERVIEW 435 TABLE 515 SHIMADZU CORPORATION: PRODUCTS OFFERED 436 TABLE 516 AURORA BIOMED INC.: COMPANY OVERVIEW 438 TABLE 517 AURORA BIOMED INC.: PRODUCTS OFFERED 438 TABLE 518 STANDARD BIOTOOLS: COMPANY OVERVIEW 439 TABLE 519 STANDARD BIOTOOLS: PRODUCTS OFFERED 440 TABLE 520 JEOL LTD.: COMPANY OVERVIEW 441 TABLE 521 JEOL LTD.: PRODUCTS OFFERED 443 TABLE 522 GILSON INCORPORATED: COMPANY OVERVIEW 444 TABLE 523 GILSON INCORPORATED: PRODUCTS OFFERED 444 TABLE 524 BIOMÉRIEUX: COMPANY OVERVIEW 445 TABLE 525 BIOMÉRIEUX: PRODUCTS OFFERED 446 TABLE 526 GREINER AG: COMPANY OVERVIEW 447 TABLE 527 GREINER AG: PRODUCTS OFFERED 448 TABLE 528 BGI GROUP: COMPANY OVERVIEW 449 TABLE 529 BGI GROUP: PRODUCTS OFFERED 449 TABLE 530 PORVAIR: COMPANY OVERVIEW 451 TABLE 531 PORVAIR: PRODUCTS OFFERED 452 TABLE 532 POLARIS GENOMICS: COMPANY OVERVIEW 453 TABLE 533 BICO: COMPANY OVERVIEW 454 TABLE 534 CREATIVE BIOARRAY: COMPANY OVERVIEW 455 TABLE 535 SPHERE BIO: COMPANY OVERVIEW 455 TABLE 536 GENSCRIPT: COMPANY OVERVIEW 456 TABLE 537 SCHRÖDINGER, INC.: COMPANY OVERVIEW 457 TABLE 538 LECO CORPORATION: COMPANY OVERVIEW 458 TABLE 539 TRANSGEN BIOTECH CO., LTD: COMPANY OVERVIEW 459 TABLE 540 BMG LABTECH: COMPANY OVERVIEW 460 TABLE 541 NANOTEMPER TECHNOLOGIES: COMPANY OVERVIEW 461 TABLE 542 MGI TECH CO., LTD.: COMPANY OVERVIEW 462 TABLE 543 ARACELI BIOSCIENCES: COMPANY OVERVIEW 463 TABLE 544 ANALYTIK JENA GMBH+CO. KG: COMPANY OVERVIEW 464 TABLE 545 BIOSOLVEIT GMBH: COMPANY OVERVIEW 465 TABLE 546 EVOSEP: COMPANY OVERVIEW 466 TABLE 547 IMPACT ANALYSIS OF SUPPLY AND DEMAND-SIDE FACTORS 478 TABLE 548 RISK ASSESSMENT 480 FIGURE 1 DRUG DISCOVERY TECHNOLOGIES MARKET SEGMENTATION AND REGIONS CONSIDERED 43 FIGURE 2 DRUG DISCOVERY TECHNOLOGIES MARKET: YEARS CONSIDERED 44 FIGURE 3 MARKET SCENARIO 47 FIGURE 4 GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET, 2023–2030 48 FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY TECHNOLOGIES MARKET, 2022–2025 48 FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF DRUG DISCOVERY TECHNOLOGIES MARKET 49 FIGURE 7 HIGH-GROWTH SEGMENTS IN DRUG DISCOVERY TECHNOLOGIES MARKET, 2025–2030 50 FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN DRUG DISCOVERY TECHNOLOGIES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 51 FIGURE 9 REAGENTS & CONSUMABLES SEGMENT AND US LED NORTH AMERICAN MARKET IN 2024 53 FIGURE 10 ASIA PACIFIC IS LIKELY TO BE FASTEST-GROWING MARKET IN DRUG DISCOVERY TECHNOLOGIES MARKET DURING FORECAST PERIOD 54 FIGURE 11 REAGENTS & CONSUMABLES TO DOMINATE MARKET DURING FORECAST PERIOD 55 FIGURE 12 DRUG DISCOVERY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56 FIGURE 13 DRUG DISCOVERY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS 65 FIGURE 14 GROWTH OF GLOBAL GDP FROM 2020 TO 2024, WITH FORECASTS UNTIL 2030 67 FIGURE 15 DRUG DISCOVERY TECHNOLOGIES MARKET: VALUE CHAIN ANALYSIS 68 FIGURE 16 DRUG DISCOVERY TECHNOLOGIES MARKET: ECOSYSTEM ANALYSIS 70 FIGURE 17 AVERAGE SELLING PRICE OF INSTRUMENTS, BY KEY PLAYER, 2024 (USD) 72 FIGURE 18 AVERAGE SELLING PRICE OF CONSUMABLES, BY KEY PLAYER, 2024 (USD) 73 FIGURE 19 AVERAGE SELLING PRICE OF INSTRUMENTS, BY REGION, 2024 (USD MILLION) 74 FIGURE 20 AVERAGE SELLING PRICE OF CONSUMABLES, BY REGION, 2024 (USD MILLION) 75 FIGURE 21 DRUG DISCOVERY TECHNOLOGIES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 80 FIGURE 22 DRUG DISCOVERY TECHNOLOGIES MARKET: INVESTMENT AND FUNDING SCENARIO, 2022–2025 (USD MILLION) 81 FIGURE 23 PATENT APPLICATIONS IN DRUG DISCOVERY TECHNOLOGIES MARKET, JANUARY 2014–DECEMBER 2024 92 FIGURE 24 IMPACT OF AI/GEN AI ON DRUG DISCOVERY TECHNOLOGIES MARKET 95 FIGURE 25 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 107 FIGURE 26 KEY BUYING CRITERIA, BY END USER 108 FIGURE 27 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET SNAPSHOT 226 FIGURE 28 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET SNAPSHOT 262 FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2024 329 FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 330 FIGURE 31 DRUG DISCOVERY TECHNOLOGIES MARKET: BRAND/PRODUCT COMPARISON 332 FIGURE 32 DRUG DISCOVERY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 335 FIGURE 33 DRUG DISCOVERY TECHNOLOGIES MARKET: COMPANY FOOTPRINT 336 FIGURE 34 DRUG DISCOVERY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 342 FIGURE 35 EV/EBITDA OF KEY VENDORS 345 FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 345 FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 350 FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2024) 357 FIGURE 39 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024) 361 FIGURE 40 REVVITY: COMPANY SNAPSHOT (2024) 366 FIGURE 41 ILLUMINA, INC.: COMPANY SNAPSHOT (2024) 371 FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2024) 376 FIGURE 43 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024) 383 FIGURE 44 BRUKER: COMPANY SNAPSHOT (2024) 387 FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2024) 391 FIGURE 46 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024) 395 FIGURE 47 TECAN TRADING AG: COMPANY SNAPSHOT (2024) 399 FIGURE 48 TAKARA BIO INC.: COMPANY SNAPSHOT (2024) 402 FIGURE 49 CORNING INCORPORATED: COMPANY SNAPSHOT (2024) 405 FIGURE 50 PACBIO: COMPANY SNAPSHOT (2024) 410 FIGURE 51 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT (2024) 414 FIGURE 52 WATERS CORPORATION: COMPANY SNAPSHOT (2024) 420 FIGURE 53 SARTORIUS AG: COMPANY SNAPSHOT (2024) 424 FIGURE 54 BD: COMPANY SNAPSHOT (2024) 428 FIGURE 55 EPPENDORF SE: COMPANY SNAPSHOT (2024) 432 FIGURE 56 SHIMADZU CORPORATION: COMPANY SNAPSHOT (2024) 436 FIGURE 57 STANDARD BIOTOOLS: COMPANY SNAPSHOT (2024) 440 FIGURE 58 JEOL LTD.: COMPANY SNAPSHOT 442 FIGURE 59 BIOMÉRIEUX: COMPANY SNAPSHOT (2024) 446 FIGURE 60 GREINER AG: COMPANY SNAPSHOT (2024) 448 FIGURE 61 PORVAIR: COMPANY SNAPSHOT (2024) 452 FIGURE 62 DRUG DISCOVERY TECHNOLOGIES MARKET: RESEARCH DESIGN 467 FIGURE 63 DRUG DISCOVERY TECHNOLOGIES MARKET: BREAKDOWN OF PRIMARIES 470 FIGURE 64 DRUG DISCOVERY TECHNOLOGIES MARKET: INSIGHTS FROM PRIMARIES 471 FIGURE 65 DRUG DISCOVERY TECHNOLOGIES MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2024) 472 FIGURE 66 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE ANALYSIS (2024) 472 FIGURE 67 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 474 FIGURE 68 DRUG DISCOVERY TECHNOLOGIES BASE NUMBER CALCULATION (SUPPLY-SIDE ANALYSIS), 2024 475 FIGURE 69 DRUG DISCOVERY TECHNOLOGIES MARKET: CAGR PROJECTIONS 476 FIGURE 70 DRUG DISCOVERY TECHNOLOGIES MARKET: DATA TRIANGULATION 477

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們